KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Accumulated Expenses: 2018-2024

Historic Accumulated Expenses for Adaptive Biotechnologies (ADPT) over the last 7 years, with Dec 2024 value amounting to $15.8 million.

  • Adaptive Biotechnologies' Accumulated Expenses rose 2.79% to $12.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.7 million, marking a year-over-year increase of 2.79%. This contributed to the annual value of $15.8 million for FY2024, which is 15.73% up from last year.
  • Adaptive Biotechnologies' Accumulated Expenses amounted to $15.8 million in FY2024, which was up 15.73% from $13.7 million recorded in FY2023.
  • In the past 5 years, Adaptive Biotechnologies' Accumulated Expenses registered a high of $15.9 million during FY2022, and its lowest value of $13.2 million during FY2020.
  • In the last 3 years, Adaptive Biotechnologies' Accumulated Expenses had a median value of $15.8 million in 2024 and averaged $15.2 million.
  • As far as peak fluctuations go, Adaptive Biotechnologies' Accumulated Expenses spiked by 62.01% in 2020, and later decreased by 14.12% in 2023.
  • Adaptive Biotechnologies' Accumulated Expenses (Yearly) stood at $13.2 million in 2020, then rose by 18.84% to $15.6 million in 2021, then grew by 1.87% to $15.9 million in 2022, then declined by 14.12% to $13.7 million in 2023, then rose by 15.73% to $15.8 million in 2024.